Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing

FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet